Authors
Latest:
Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue SarcomaAlessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Latest:
Novel Tubulin-Targeting Therapies Make HeadwayClinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.
Latest:
Dr. Hoskins on the Impact of Race on Breast Cancer OutcomesKent Hoskins, MD, discusses the impact of race on breast cancer outcomes.
Latest:
Dr. Ayers on the Evolving Treatment Landscape in CLLEmily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.
Latest:
Dr Dondossola on the Importance of Studying Bone Metastasis in RCCEleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.
Latest:
Dr Grieb on the Need for Novel Biomarkers in CRCBrian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Sfakianos on Importance of Restaging Transurethral Resection of Bladder TumorsJohn P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.
Latest:
Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in CancerAatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.
Latest:
Dr Shouse on the Importance of NGS Testing in Follicular LymphomaGeoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.
Latest:
Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic CancerLacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.
Latest:
Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood CancerMatthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.
Latest:
Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLCEdgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.
Latest:
Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial CancerSarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.
Latest:
Dr Mikhael on Unmet Needs to Be Addressed in Multiple MyelomaJoseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.
Latest:
Dr Lattanzi on Findings From the PROpel trial in mCRPCMike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr Corvigno on Chemotherapy-Related Clonal Hematopoiesis in Ovarian CancerSara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.
Latest:
Dr Wagner or the Potential Value of Immunotherapy in AngiosarcomaMichael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.
Latest:
Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCLCarmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Latest:
Dr. Gradishar on the Significance of Drug Development in HER2+ Breast CancerWilliam Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.
Latest:
Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine NeoplasmsTucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.
Latest:
Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast CancerJulie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade GliomaJordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.
Latest:
Dr. Nagle on Investigational Cellular Therapies in Multiple MyelomaSarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.
Latest:
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCLMarie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.
Latest:
Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLCAndrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.
Latest:
Dr. Vorobiof on the Impact of Financial Toxicity in the Field of OncologyDaniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.
.jpg?fit=crop&auto=format)
